BridgeMD
HAMLETT. Handling Antipsychotic Medication: Long-term Evaluation of Targeted Treatment. A study comparing continuation versus discontinuation/dose reduction of antipsychotic medication in patients remitted after a first episode of psychosis
EU CTIS ID: 2024-518769-80-00
What this study is testing
The HAMLETT study investigates the effects of maintenance treatment versus discontinuation/dose reduction of antipsychotic medication after remission of first episode psychosis on personal and social functioning, This question not only concerns short-term effects (i.e. 1 or 2 years), but also long-term functioning (3-4 years).
- Therapeutic use (Phase IV)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- The participant has had a first episode of psychosis and uses antipsychotic medication.
- Psychotic symptoms are in remission for 3-6 months.
- Age 16-60 years.
- The participant understands the study and is able to provide written informed consent.
- HAMLETT is the only medical-scientific medication study in which the patient participates.
- Sufficient command of the Dutch language.
You likely can't join if
- Dangerous or harmful behaviour (i.e. behaviour with a risk of severe physical injury, or actual physical injury inflicted, to self or others) occurred during the psychosis.
- Coercive treatment (based on a judicial ruling).
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 0-17 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.